Literature DB >> 31332496

Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18F]MK6240 in human subjects.

Nicolas J Guehl1, Dustin W Wooten2, Daniel L Yokell2, Sung-Hyun Moon2, Maeva Dhaynaut2, Samantha Katz2, Kirsten A Moody2, Codi Gharagouzloo2, Aurélie Kas3, Keith A Johnson2, Georges El Fakhri2, Marc D Normandin2.   

Abstract

PURPOSE: [18F]MK6240 was developed for PET imaging of tau aggregates, which are implicated in Alzheimer's disease. The goal of this work was to evaluate the kinetics of [18F]MK6240 and to investigate different strategies for in-vivo quantification of tau aggregates in humans.
METHODS: Thirty-five subjects, consisting of 18 healthy controls (CTRL), 11 subjects with mild cognitive impairment (MCI) and six with Alzheimer's Disease (AD), underwent dynamic [18F]MK6240 PET scans. Arterial blood measurements were collected in 16 subjects (eight CTRLs, six MCIs and two AD) to measure whole blood and plasma concentration time courses. Radiometabolite analysis was performed on a subset of plasma samples. Various compartmental model configurations as well as the Logan and multilinear analysis (MA1) graphical methods with arterial plasma input function were tested. Simplified reference tissue methods were investigated, including Logan distribution volume ratio (DVR), multilinear reference tissue method (MRTM2), and static SUV ratio using the cerebellum as a reference region.
RESULTS: Whole blood:plasma ratio stabilized to 0.66 ± 0.01 after 15 min. Percent parent in plasma (%PP) followed a single exponential and ranged from 0 to 10% at 90 min. [18F]MK6240 in gray matter peaked quickly (SUV > 2 at ~3 min). The preferred compartmental model was a reversible two-tissue compartment model, with the blood contribution included as a model parameter (2T4k1v). Compartmental and graphical analysis methods with arterial input functions yielded concordant results, but rapid metabolism raised challenges for blood-based quantification. MCI and AD subjects demonstrated a broad range of VT as compared to CTRL subjects. DVR from MRTM2 and Logan reference tissue methods correlated with DVR calculated indirectly from compartmental modeling, but underestimation was observed in data sets with very high binding (DVR > 3). SUVR also underestimated indirect DVR from blood-based analyses in high binding regions, although a non-linear relationship was exhibited.
CONCLUSIONS: [18F]MK6240 exhibited a wide dynamic range of uptake, with binding patterns in MCI/AD subjects consistent with neurofibrillary tau deposition patterns. Linearized reference tissue methods using an estimated average tissue-to-plasma efflux constant [Formula: see text] and static SUVR agreed well with blood-based methods for most data sets; however, discrepancies were noted in the highest binding cases. Caution should therefore be exercised in application of simplified methods to such data sets, and in quantitative interpretation of corresponding outcomes.

Entities:  

Keywords:  Kinetic modeling; Pharmacokinetics; Positron emission tomography; Tau; [18F]MK6240

Mesh:

Substances:

Year:  2019        PMID: 31332496      PMCID: PMC6709592          DOI: 10.1007/s00259-019-04419-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  26 in total

1.  Column-switching HPLC for the analysis of plasma in PET imaging studies.

Authors:  J Hilton; F Yokoi; R F Dannals; H T Ravert; Z Szabo; D F Wong
Journal:  Nucl Med Biol       Date:  2000-08       Impact factor: 2.408

Review 2.  A review of graphical methods for tracer studies and strategies to reduce bias.

Authors:  Jean Logan
Journal:  Nucl Med Biol       Date:  2003-11       Impact factor: 2.408

3.  Strategies to improve neuroreceptor parameter estimation by linear regression analysis.

Authors:  Masanori Ichise; Hiroshi Toyama; Robert B Innis; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2002-10       Impact factor: 6.200

Review 4.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

5.  Compartmental analysis of diprenorphine binding to opiate receptors in the rat in vivo and its comparison with equilibrium data in vitro.

Authors:  V J Cunningham; S P Hume; G R Price; R G Ahier; J E Cremer; A K Jones
Journal:  J Cereb Blood Flow Metab       Date:  1991-01       Impact factor: 6.200

6.  Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain.

Authors:  Masanori Ichise; Jeih-San Liow; Jian-Qiang Lu; Akihiro Takano; Kendra Model; Hiroshi Toyama; Tetsuya Suhara; Kazutoshi Suzuki; Robert B Innis; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2003-09       Impact factor: 6.200

7.  Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.

Authors:  J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley
Journal:  J Cereb Blood Flow Metab       Date:  1990-09       Impact factor: 6.200

8.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease.

Authors:  P V Arriagada; J H Growdon; E T Hedley-Whyte; B T Hyman
Journal:  Neurology       Date:  1992-03       Impact factor: 9.910

Review 9.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 10.  FSL.

Authors:  Mark Jenkinson; Christian F Beckmann; Timothy E J Behrens; Mark W Woolrich; Stephen M Smith
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

View more
  12 in total

1.  Fitting of late dynamic [18F]MK6240 PET scans for in vivo tau quantification.

Authors:  Eric Laffon; Sébastien Buj; Henri de Clermont; Roger Marthan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-16       Impact factor: 9.236

2.  Reply to: Fitting of late dynamic [18F]MK6240 PET scans for in vivo tau quantification.

Authors:  Nicolas J Guehl; Dustin W Wooten; Georges El Fakhri; Marc D Normandin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-06-18       Impact factor: 9.236

3.  Spatially constrained kinetic modeling with dual reference tissues improves 18F-flortaucipir PET in studies of Alzheimer disease.

Authors:  Yun Zhou; Shaney Flores; Syahir Mansor; Russ C Hornbeck; Zhude Tu; Joel S Perlmutter; Beau Ances; John C Morris; Robert J Gropler; Tammie L S Benzinger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-18       Impact factor: 9.236

4.  NRM 2021 Abstract Booklet.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2021-12       Impact factor: 6.960

Review 5.  Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Authors:  Gérard N Bischof; Alessandra Dodich; Marina Boccardi; Thilo van Eimeren; Cristina Festari; Henryk Barthel; Oskar Hansson; Agneta Nordberg; Rik Ossenkoppele; Osama Sabri; B Frisoni G Giovanni; Valentina Garibotto; Alexander Drzezga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-16       Impact factor: 9.236

6.  Direct Comparison of the Tau PET Tracers 18F-Flortaucipir and 18F-MK-6240 in Human Subjects.

Authors:  Alexandra Gogola; Davneet S Minhas; Victor L Villemagne; Ann D Cohen; James M Mountz; Tharick A Pascoal; Charles M Laymon; N Scott Mason; Milos D Ikonomovic; Chester A Mathis; Beth E Snitz; Oscar L Lopez; William E Klunk; Brian J Lopresti
Journal:  J Nucl Med       Date:  2021-04-16       Impact factor: 11.082

7.  Impact of meningeal uptake and partial volume correction techniques on [18F]MK-6240 binding in aMCI patients and healthy controls.

Authors:  Nathalie Mertens; Laura Michiels; Greet Vanderlinden; Mathieu Vandenbulcke; Robin Lemmens; Koen Van Laere; Michel Koole
Journal:  J Cereb Blood Flow Metab       Date:  2022-01-21       Impact factor: 6.960

8.  Tau PET imaging with 18F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study.

Authors:  Andre Mueller; Santiago Bullich; Olivier Barret; Jennifer Madonia; Mathias Berndt; Caroline Papin; Audrey Perrotin; Norman Koglin; Heiko Kroth; Andrea Pfeifer; Gilles Tamagnan; John P Seibyl; Kenneth Marek; Susan De Santi; Ludger M Dinkelborg; Andrew W Stephens
Journal:  J Nucl Med       Date:  2019-11-11       Impact factor: 11.082

9.  Evaluation of Dosimetry, Quantitative Methods, and Test-Retest Variability of 18F-PI-2620 PET for the Assessment of Tau Deposits in the Human Brain.

Authors:  Santiago Bullich; Olivier Barret; Cristian Constantinescu; Christine Sandiego; Andre Mueller; Mathias Berndt; Caroline Papin; Audrey Perrotin; Norman Koglin; Heiko Kroth; Andrea Pfeifer; Gilles Tamagnan; Jennifer Madonia; John P Seibyl; Kenneth Marek; Susan De Santi; Ludger M Dinkelborg; Andrew W Stephens
Journal:  J Nucl Med       Date:  2019-11-11       Impact factor: 11.082

10.  A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using [18F]MK-6240.

Authors:  Ronald Boellaard; Michel Koole; Guilherme D Kolinger; David Vállez García; Talakad G Lohith; Eric D Hostetler; Cyrille Sur; Arie Struyk
Journal:  EJNMMI Res       Date:  2021-05-27       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.